Obesity rather than neoadjuvant chemotherapy predicts steatohepatitis in patients with colorectal metastasis

Am J Surg. 2013 Jun;205(6):685-90. doi: 10.1016/j.amjsurg.2012.07.034. Epub 2013 Feb 4.

Abstract

Introduction: Neoadjuvant chemotherapy has been associated with an increased risk of surgery because of chemotherapy-associated steatohepatitis and sinusoidal obstruction. The aim of the current study was to assess for other predictors of steatohepatitis and sinusoidal obstruction and to determine the role of obesity as a risk factor in patients with colorectal liver metastasis (CLM).

Methods: An institutional review board-approved prospectively maintained database of 1,605 patients who underwent hepatic procedures for CLM from 2001 to 2009 was reviewed.

Results: In a review of 208 resected patients, body mass index was the only predictor of liver injury according to multivariate analysis (P < .001, odds ratio = 3.88). Diabetes, neoadjuvant chemotherapy, sleep apnea, alcohol use, tobacco use, age, and sex were not significant predictors. Among preoperative chemotherapy patients, BMI was a predictor of chemotherapy liver injury according to multivariate analysis (P < .0001). The rate of obesity (BMI >30) was 36%, and among obese patients (BMI >30) the rate of steatosis or steatohepatitis was 39%.

Conclusions: Obesity is the strongest predictor of steatosis and steatohepatitis in patients with CLM, and this risk is independent of the use of preoperative chemotherapy.

MeSH terms

  • Antineoplastic Agents / therapeutic use
  • Body Mass Index
  • Colorectal Neoplasms / pathology*
  • Fatty Liver / etiology*
  • Female
  • Hepatectomy
  • Humans
  • Liver Neoplasms / drug therapy
  • Liver Neoplasms / secondary*
  • Liver Neoplasms / surgery
  • Male
  • Middle Aged
  • Multivariate Analysis
  • Neoadjuvant Therapy
  • Obesity / complications*

Substances

  • Antineoplastic Agents